Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwMyeloma 2015 | Novel HDAC6 inhibitor, ricolinostat, for the treatment of multiple myeloma

Noopur Raje • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma

At the Myeloma 2015 meeting, Dr Noopur Raje (Massachusetts General Hospital, Boston, MA) discusses the clinical development of the selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, for the treatment of multiple myeloma. Clinical results to date suggest that ricolinostat is likely to operate synergistically with other agents.

More from Noopur Raje

2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals